IRB #

STUDY00016941

Title

Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Principal Investigator

Michael Heinrich

Study Purpose

We are looking for people newly diagnosed with chronic phase chronic myeloid leukemia (CP-CML) who have not yet started treatment with BCR-ABL1 tyrosine kinase inhibitors (TKIs). This study focuses on the cardiovascular and metabolic risks of TKIs.

This study is observational and does not require you to take any medication aside from the treatment that you are getting under the medical care of your doctor. No compensation is provided. You may not personally benefit from being in this study. However, by serving as a participant, you may help us learn how to benefit patients in the future

Medical Condition(s)

CML
Chronic Myeloid Leukemia
Chronic Myelogenous Leukemia
cardiovascular
metabolic
TKI
BCR-ABL1

Eligibility Criteria

You must be:
1. at least 18 years of age,
2. newly diagnosed chronic phase of Ph+ or CP-CML, confirmed with cytogenetic and/or molecular testing at baseline
3. going to start taking dasatinib, imatinib, or nilotinib, but have not yet started treatment
4. willing and able to come to routine office visits

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

This research study is expected to last 24 months.

Minors Included

No

Contact

Knight Cancer Intake Center: (503)494-7999

Sponsor

Bristol-Myers Squibb

Recruitment End

02/17/2027

Compensation Provided

No


Go Back